Quizartinib: Completed Phase II enrollment

The partners completed enrollment of 333 patients in the open-label, international Phase II trial evaluating 90 and 135 mg oral quizartinib once daily in female and male patients, respectively. The partners also presented updated interim data from 62 evaluable patients in the trial at the American Society of Hematology meeting in San Diego. The data are in line with previously reported interim data from 53 evaluable patients (see BioCentury, June 27). Data from all patients in the trial are expected next year. ...